Article citationsMore>>

Khattab, A.A., Hamm, C.W., Senges, J., Toelg, R., Geist, V., Bonzel, T., Kelm, M., Levenson, B., Neumann, F.J., Nienaber, C.A., Pfannebecker, T., Sabin, G., Schneider, S., Tebbe, U. and Richardt, G. (2007) Sirolimus-eluting stent treatment for unprotected versus protected left main coronary artery disease in widespread clinical routine: 6-month and 3-year clinical follow-up results from the prospective multicentre German cypher registry. Heart, 93, 1251-1255. doi:10.1136/hrt.2007.104703

has been cited by the following article:

• TITLE: Unprotected left main coronary artery stenting with everolimus (Xience V) drug-eluting stents: A single center retrospective experience

  AUTHORS: Juan C. Fernandez-Guerrero, Juan A. Herrador, Manuel Guzman, Victor Aragon, Carmen Adamuz

  KEYWORDS: Percutaneous Coronary Interventions; “Off Label” Lesions; Prognosis

  JOURNAL NAME: World Journal of Cardiovascular Diseases, Vol.3 No.2, April 25, 2013

  ABSTRACT: Objectives: We sought to evaluate the efficacy and safety of unrestricted implantation of everolimus eluting stent Xience V (EES-XV) in a cohort of real- world patients with unprotected left main coronary disease (ULMCD). Background: The second-generation EES-XV stent is currently one of the most commonly used drug-eluting stents in clinical practice. It has been shown to be superior to paclitaxel-eluting stents, but its relative merits on unprotected left main coronary disease have been less extensively assessed. Methods: Between 2007 and 2010, in this single-center registry, we evaluated the clinical outcomes of 98 patients with ULMCD who underwent percutaneous coronary intervention (PCI) with EES-XV. Results: There were no in-hospital deaths. At 25.63 ± 14.41 months of follow-up, 17 patients (17.3%) experienced major adverse coronary event (MACE), death from cardiovascular disease (n = 6; 6.1%) and target lesion revascularization (TLR; n = 7; 7.1%). The predictors of death from cardiovascular disease were: previous PCI and left ventricular dysfunction. The only predictor of TLR was the placement of 2 stents in the left main coronary artery. Conclusions: In this single- center real-world registry, we found that elective ULMCD stenting with EES-XV provided good short-, medium- and long-term outcomes, with an estimated cumulative need for TLR of 7.1%, a cardiac mortality rate of 6.1%, and a MACE rate of 17.3% at 2 years.